InvestSMART

Australian Clinical Labs Limited (ASX: ACL) - Announcements

Current share price for ACL : $2.920 0.04 (1.39%)+

ASX company news and announcements for Australian Clinical Labs Limited (ACL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Clinical Labs Limited (ACL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Clinical Labs Limited (ACL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Clinical Labs Limited (ACL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$545 Change in substantial holding 13 Nov 2015 4:42PM $0.091 $2.920 risen by 3,108.79%
$545 Change of Company Registered Address 11 Nov 2015 11:11AM $0.092 $2.920 risen by 3,073.91%
$545 Results of Meeting 10 Nov 2015 4:33PM $0.087 $2.920 risen by 3,256.32%
$545 Appendix 3B 2 Nov 2015 8:20AM $0.088 $2.920 risen by 3,218.18%
$545 Appendix 4C - quarterly 28 Oct 2015 12:16PM $0.088 $2.920 risen by 3,218.18%
$545 Change in substantial holding 19 Oct 2015 4:58PM $0.086 $2.920 risen by 3,295.35%
$545 Notice of Annual General Meeting/Proxy Form 9 Oct 2015 9:24AM $0.082 $2.920 risen by 3,460.98%
$545 Appendix 4G Corporate Governance Disclosures 7 Oct 2015 9:49AM $0.081 $2.920 risen by 3,504.94%
$545 Annual Report to shareholders 7 Oct 2015 9:49AM $0.081 $2.920 risen by 3,504.94%
$545 Change in substantial holding 29 Sep 2015 6:22PM $0.076 $2.920 risen by 3,742.11%
$545 Sale of Fondaparinux IP 25 Sep 2015 8:26AM $0.035 $2.920 risen by 8,242.86%
$545 Alchemia Financial Results for year ended 2015 28 Aug 2015 8:38AM $0.034 $2.920 risen by 8,488.24%
$545 Preliminary Final Report 28 Aug 2015 8:29AM $0.034 $2.920 risen by 8,488.24%
$545 Update on Conditional Sale of Oncology Subsidiary 3 Aug 2015 10:28AM $0.037 $2.920 risen by 7,791.89%
$545 Cash Result for the Quarter Ending 30 June 2015 31 Jul 2015 9:15AM $0.032 $2.920 risen by 9,025%
$545 Appendix 4C - quarterly 31 Jul 2015 9:05AM $0.032 $2.920 risen by 9,025%
$545 Chairman Appointment 10 Jul 2015 9:48AM $0.033 $2.920 risen by 8,748.48%
$545 Final Director's Interest Notice 9 Jul 2015 10:16AM $0.033 $2.920 risen by 8,748.48%
$545 Retirement of Non-Executive Director 9 Jul 2015 9:21AM $0.033 $2.920 risen by 8,748.48%
$545 Withdrawal of Requisition of General Meeting 6 Jul 2015 5:13PM $0.035 $2.920 risen by 8,242.86%
$545 Alchemia Assignment of VAST Technology 3 Jul 2015 10:02AM $0.034 $2.920 risen by 8,488.24%
$545 Conditional Sale of Oncology Subsidiary 1 Jul 2015 8:28AM $0.032 $2.920 risen by 9,025%
$545 Initial Director's Interest Notice 26 Jun 2015 9:19AM $0.033 $2.920 risen by 8,748.48%
$545 Appointment of Non-Executive Director 26 Jun 2015 8:47AM $0.033 $2.920 risen by 8,748.48%
$545 Change in substantial holding 25 Jun 2015 4:37PM $0.033 $2.920 risen by 8,748.48%

776 - 800 of 1019 results

Page 32 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.